Research and Markets - High Growth in Generics Market Forecast to Continue Strongly In Next Five Years as Penetration of Generics in Pharmaceutical Sales Still Comparatively Low in Key Markets Such As the UK and France

Research and Markets (researchandmarkets.com/reports/c9335) has announced the addition of Growth Strategies in Generics: Innovative and aggressive strategies and their impact on branded pharmaceuticals to their offering.

(PRWEB) November 17, 2004 -- Research and Markets (http://www.researchandmarkets.com/reports/c9335) has announced the addition of Growth Strategies in Generics: Innovative and aggressive strategies and their impact on branded pharmaceuticals to their offering.

The generics market in both Europe and the US is highly dynamic. Growth is high, and forecast to continue strongly in the next five years as penetration of generics in pharmaceutical sales is still comparatively low in key markets such as the UK and France. At the same time, the distinctions between some generics companies and traditional, R&D-led pharmaceutical companies are blurring as generics companies move up-stream and invest in R&D while pharmaceutical companies such as Novartis, Sanofi and Merck retain successful generic subsidiaries.However, market saturation threatens to erode profit margins for generics companies as prices are forced lower, while manufacturers outside Europe and the US take an increasing market share. This Management Report assesses the growth prospects of generic drugs in Europe and the US. The report gives a detailed analysis of the impact of new legislation, the strategies of the key players and market pressures on the generic and branded drug sectors.

Key findings in this report include:

- Indian manufacturers represent the greatest threat to the existing generics market, and will force both mainstream pharmaceutical companies and established generics companies to explore alliances and acquisitions there.

- Generic drug sales are forecast by the majority of branded drug and generic drug company executives to be above 5%. One third of all executives forecast growth above 10%.

- On balance, new legislation in both the EU and the US has been more beneficial to generics companies, lowering barriers to entry and speeding up the approvals process.

- The distinction between established generics companies and mainstream pharmaceutical companies is blurring as companies such as Teva and Ranbaxy increase their investment in R&D in a bid to push their product portfolios upstream.

- Biogenerics will reach Europe before the US due to recent legislative changes. Lower regulatory barriers have meant that Eastern Europe is an area of expertise for biogenerics.

This report answers questions such as:

1. What will be the impact of Indian and Chinese manufacturers on established generic drug manufacturers?

2. How will each new piece of legislation in Europe and the US affect the growth strategies of generic and branded pharmaceutical companies?

3. How are generics companies seeking to diversify and develop in the future?

4. What are the key trends that will drive generics growth in Europe and the US?

5. What successful strategies are generics companies using and how are these evolving in the face of increasing market pressures?

6. Which country markets will see the highest growth and what are the most attractive therapy areas for generics companies to target?

Contents Include:

- Market overview

- Successful US strategies

- Successful European strategies

- US legislation and its impact

- European legislation and its impact

- US barriers to generics growth

- European barriers to generics growth

- Future prospects and conclusions

For more information visit http://www.researchandmarkets.com/reports/c9335

Laura Wood

Senior Manager

Research and Markets

press@researchandmarkets.com

Fax: +353 1 4100 980

###